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Introduction: Despite being a common disease, data on vertigo management in a real-
world setting are scarce.
Aims:To provide information on the vertigo and its management in a real-world setting.
Methods: Data were collected from 4,294 patients with vertigo in 13 countries over
28 months via a multi-national, non-interventional observational study (the so-called
REVERT registry). Data included medical history and details of anti-vertigo therapy. “Clini-
cal global impression” (CGI) of severity (CGI-S) was assessed at baseline (V1) and then at
6 months follow-up (V2) along with CGI change (CGI-C). All variables were analyzed descrip-
tively.
Results: The majority of patients were female, >40 years of age, and almost half had co-
morbid cardio-vascular disease. Diagnoses were split into four categories: 37.2% “other
vertigo of peripheral vestibular origin,” 26.9% benign paroxysmal positional vertigo (BPPV),
20.5% “peripheral vestibular vertigo of unknown origin,” and 15.4% Ménière’s disease
(MD). Betahistine was the most commonly prescribed therapy prior to and after enroll-
ment, and was followed by piracetam, ginkgo biloba, and diuretics. MD had the highest
proportion of betahistine treated patients. Almost half of patients were “moderately ill” at
V1 based on CGI-S. At V2, patient distribution moved toward “less severe illness” (91.0%
improved).The greatest improvements were in the more severely ill, and those with BPPV
or “other vertigo of peripheral origin.”
Conclusion: There was a reduction in illness severity over the course of the study, some
of which is likely to be due to pharmacological intervention. Further studies are needed to
confirm these results.
Keywords: vertigo, treatment, betahistine, “observational study,” “registry”
INTRODUCTION
Vertigo, defined as an erroneous sense of motion and unsteadiness
(Swartz and Longwell, 2005; Kuo et al., 2008a; Brandt et al., 2009;
Strupp et al., 2011), is a relatively common condition, yet defin-
itions vary and management guidelines are often contradictory.
A survey in Germany, for example, reported that dizziness/vertigo
had a prevalence of 22.9% in the last 12 months and an incidence of
3.1% (Neuhauser, 2007). The most commonly reported present-
ing symptom is dizziness (Labuguen, 2006) although symptoms
can also include loss of balance, nausea (Kuo et al., 2008a), vom-
iting (Clark et al., 1994), light-headedness, and difficulty standing
or walking (Hanley et al., 2001; Labuguen, 2006).
The most common causes of vertigo are vestibular disor-
ders including: benign paroxysmal positional vertigo (BBPV),
Ménière’s disease (MD), and vestibular neuritis (Hanley et al.,
2001; Kuo et al., 2008a,b). Patients are variously affected depend-
ing on the underlying cause of disease (Hanley et al., 2001). For
example, in BPPV, vertigo develops suddenly, lasts ∼1 min and
is typically induced by changes of the head or body position. By
contrast, in MD, attacks can last up to several hours (Saeed, 1998;
Strupp and Brandt, 2008).
There is no single effective medication for vertigo and in clinical
practice a combination of drugs are used, including antihistamines
and anti-emetics (Della Pepa et al., 2006; Kuo et al., 2008b). Acutely
administered anti-vertiginous medications can be given to treat
the attack; however, these have limited benefit and no effect in
those patients where episodes only last a few seconds (Swartz and
Longwell, 2005; Brandt et al., 2009).
While dizziness and vertigo are often reported as common and
frustrating complaints in general practice (Hanley et al., 2001;
Labuguen, 2006), and can account for a significant number of
consultations (Hanley et al., 2001) there is a lack of agreement on
the treatment and management of vertigo both from national and
regional perspectives.
Little is known about the therapies most commonly prescribed
for vertigo, compliance with these therapies and their overall effect
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on illness. A vertigo registry was specifically established to provide
information about patients with vertigo in terms of the clinical
characteristics of the illness and to assess the potential economic
effects of vertigo. This report covers the clinical and demographic
findings from the registry.
MATERIALS AND METHODS
STUDY DESIGN AND PATIENT INCLUSION
The Registry to Evaluate the burden of disease in VERTigo
(REVERT) was established to collect data for a multi-national,
non-interventional observational study of patients with vertigo.
Investigators, which included Ear Nose and Throat Specialists
(ENTs), Neurologists, General Practitioners, and Accident and
Emergency physicians, were recruited by representatives of Solvay
pharmaceuticals (now Abbott). The registry enrolled patients
from 13 countries (Algeria, Czech Republic, Egypt, Germany,
Hungary, Lithuania, Malaysia, Morocco, Russia, Slovenia, South
Africa, Tunisia, and Ukraine) and collected data over a period of
28 months. Participating countries were selected based on will-
ingness to participate, followed national regulations, and attained
ethical approval locally. Investigators recruited their next two con-
secutive patients who were diagnosed with a new onset of vertigo of
peripheral origin (either as first diagnosis for the enrolling physi-
cian or as a new consultation) and included those with BPPV, MD,
other vertigo of peripheral vestibular origin, and/or peripheral
vestibular vertigo of unknown pathology. The case-report form
used for the purpose of the study did not allow to further differ-
entiate the diagnoses of patients included in the category “other
vertigo of peripheral vestibular origin.” No further inclusion crite-
ria were defined and there were no specific instructions regarding
treatment implementation, diagnostics, or on-going examination
schedule to allow for real-world understanding of the complexities
of vertigo diagnosis, treatment, and prognosis.
Data were collected from April 2007 to August 2009; participat-
ing investigators collected information at baseline and at 6 months
follow-up. Case-report forms were used to record demographic
information; diagnosis, age grouping, gender, and clinical infor-
mation; significant medical history, anti-vertigo therapy, adverse
events, and “clinical global impression” (CGI) score. Significant
medical history included documentation of concomitant illness
including cardio-vascular disease, hormonal dysfunction, neu-
rological disorder (such as Parkinson disease, epilepsy, multiple
sclerosis), cranial trauma, cancer, psychological disorder, or drug
abuse. Anti-vertigo therapy included documentation of vestibular
rehabilitation therapy as well as prescription of betahistine, pirac-
etam, ginkgo biloba, benzodiazepines, diuretics, homeopathics,
prochlorperazine, antihistamines, and other vertigo therapy; the
case-report form also included the following question: “As a ther-
apy of vertigo symptoms, following treatment is considered for
this patient: surgery (yes/no), intratympanic gentamycin treat-
ment (yes/no).” The CGI is a 3-item observer-rated scale used
in this registry to measure illness severity (CGI-S), and global
improvement or change (CGI-C) (U.S. Department of Health,
1976). The CGI-S is rated on a 7-point scale, with the sever-
ity of illness scale using a range of responses. CGI-C scores
also range from 1 through to 7. CGI-S was assessed at baseline
based on the patient’s description of their condition for the 2 days
preceding the visit and classified as, “normal not ill at all,” “bor-
derline ill,” “mildly ill,” “moderately ill,” “markedly ill,” “severely
ill,”“among the most extremely ill patients.” Evaluation of change
in the patients’ condition (CGI-C) was assessed by estimated
improvement from baseline to follow-up as: “not assessed,” “very
much improved,” “much improved,” “minimally improved,” “no
change,”“minimally worse,”“much worse,”“very much worse,”and
[“worsened” (only in French documentation)]. The classes “very
much improved” “much improved” and “minimally improved”
were further summarized as “improved.” The classes “very much
worse” “much worse” and “minimally worse” were further sum-
marized as “worsened.” Any serious adverse drug reactions were
reported. The study was conducted according to accepted stan-
dards of good clinical practice, in agreement with the latest ver-
sion of the Declaration of Helsinki and in keeping with local
regulations. Informed consent was obtained from all subjects
and was archived by the study investigators according to local
requirements.
STATISTICAL ANALYSIS
All summary statistics were performed using SAS software (version
9.2). All analysis variables were analyzed descriptively. Statistical
significance was not determined in this study. Discrete data were
summarized presenting counts and percentages, missing values
were not considered for the calculation of percentages. Analysis of
CGI is based on data from patients with a baseline and follow-up
visit. CGI-C were analyzed in shift tables, comparing baseline with
follow-up.
RESULTS
DEMOGRAPHICS
A total of 4,294 patients were enrolled in the registry from 618
different international centers; of these, a total of 4,121 composed
the first data set consisting of patients suitable for inclusion and
providing data on prior medical history. Data set two consisted
of 4,105 patients who provided data at baseline and contributed
to descriptive statistics (Table 1) and of 3,533 (82.3%) patients
who attended both baseline and follow-up visits and so provided
complete information and met the requirements for inclusion in
the statistical analysis.
The majority of patients were female (65.3%) and over 65%
were between the ages of 41 and 70 years. The mean age at diagnosis
was 56.1 years (SD 15.07 range 13–98 years; n= 4,093); only a very
small number of patients were below the age of 20 years (0.7%).
The most common diagnosis was “other vertigo of peripheral
vestibular origin” (37.2%), followed by BPPV (26.9%), peripheral
vestibular vertigo of unknown origin (20.5%), and MD (15.4%).
Diagnosis at baseline visit, when split by gender, showed approx-
imately the same distribution, with “other vertigo of peripheral
vestibular origin” being the most frequent diagnosis.
MEDICAL HISTORY
Any significant medical history was documented at baseline, visit
1, and is documented in Table 2. A total of 429 patients had missing
data on medical history. Of the 3,676 patients providing medical
history, almost half (46.3%) had cardio-vascular disease. In addi-
tion, 17.2% had hormonal dysfunction, e.g., diabetes, and 15.2%
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Table 1 | Demographics at baseline.
Variable n (%)
COUNTRY (n=4,105)
Algeria 274 (6.7)
Czech Republic 559 (13.6)
Egypt 168 (4.1)
Germany 99 (2.4)
Hungary 1,320 (32.2)
Lithuania 202 (4.9)
Malaysia 354 (8.6)
Morocco 118 (2.9)
Russia 253 (6.2)
Slovenia 130 (3.2)
South Africa 34 (0.8)
Tunisia 185 (4.5)
Ukraine 409 (10.0)
GENDER (n=4,079)*
Male 1,417 (34.7)
Female 2,662 (65.3)
AGE RANGES,YEARS (n=4,093)**
≤20 29 (0.7)
21–30 181 (4.4)
31–40 437 (10.7)
41–50 799 (19.5)
51–60 1,079 (26.4)
61–70 816 (19.9)
71–80 548 (13.4)
>80 204 (5.0)
DIAGNOSIS (n=4,048)***
Ménière’s disease 625 (15.4)
Benign paroxysmal positional vertigo 1,090 (26.9)
Other vertigo of peripheral vestibular origin 1,504 (37.2)
Peripheral vestibular vertigo of unknown origin 829 (20.5)
*n= 26missing data on gender; **n=12missing data on age; ***n=57missing
data on diagnosis.
had psychiatric disorders. There were also reports of neurological
disorders, cranial tumors, neoplasms, and drug/alcohol abuse.
Multiple entries were possible.
TREATMENTS FOR VERTIGO
Treatments prior to inclusion in the registry were recorded, with
any treatment prescribed at baseline, and at follow-up.
Prior to inclusion in the registry, the most commonly pre-
scribed therapy was betahistine (26.6%). Piracetam was used by
11.5%, ginkgo biloba by 5.7%, and diuretics by 5.3%. In addi-
tion, patients were also using benzodiazepines, calcium antago-
nists, neuroleptics, antihistamines, and homeopathic medications
(Table 3). Co-prescription of treatments was common.
The administration of medicines prior to entry into the reg-
istry was also stratified by diagnosis. Again, the most commonly
prescribed medication was betahistine, used in 34.8% of patients
with MD (218 of 627), 24.6% of patients with BPPV (268 of 1,091),
23.6% of those with peripheral vestibular vertigo of unknown ori-
gin (196 of 832), and in 22.8% of patients with other vertigo of
Table 2 | Patients with significant medical history at baseline
(n=3,676)***.
Medical history Total n (%)
Cardiac/vascular disease 1,702 (46.3)
Hormonal dysfunction 634 (17.2)
Neurologic disorder 338 (9.2)
Cranial trauma 204 (5.5)
Neoplasm 133 (3.6)
Psychiatric disorder 558 (15.2)
Drug/alcohol abuse 107 (2.9)
***n=429 missing data on medical history.
peripheral vestibular origin (344 of 1,512). Patients affected by MD
had the highest proportion of betahistine treatment when com-
pared with the other diagnosis groups. Patients affected by “other
vertigo of peripheral origin” received piracetam more frequently
(13.8%) than any other patients. Patients affected by “peripheral
vestibular vertigo of unknown origin” received benzodiazepines
(4.8%) as well as neuroleptics (3.2%) more frequently and ginkgo
biloba less frequently (4.3%) than patients in the other treatment
groups.
TREATMENT FOR VERTIGO AFTER ENROLLMENT
Prescription of a treatment after enrollment to the registry was at
the discretion of the participating physician and was not manda-
tory. The most common treatment started at both visits was
betahistine with 66.6% of subjects prescribed this drug at visit
1 and 21.5% at visit 2 (Table 3). Piracetam was reported to be
prescribed in less than 15.0% of patients at each visit (Table 3).
Drug treatment at baseline and at follow-up was also stratified
by diagnosis; overall, betahistine was prescribed in the majority of
patients in each diagnosis group. Marginally more patients with
MD received betahistine than any other diagnosis group (Table 4).
By contrast, piracetam was prescribed more often in patients with
“other vertigo of peripheral origin” than in any other diagnostic
group.
In addition to these treatments, surgery as a therapy for vertigo
symptoms was considered (but not necessarily undertaken) for
55 patients at baseline and intratympanic gentamycin treatment
was also considered (but not necessarily undertaken) for 45 of the
4,121 patients at baseline.
CLINICAL GLOBAL IMPRESSION
CGI-S was documented at baseline and follow-up visit as shown in
Figure 1. Almost half of patients (43.3%) were classified as “mod-
erately ill” at baseline. Roughly one quarter of patients were classi-
fied as “mildly ill” (22.2%), one fifth as “markedly ill” (20.0%), and
only a small minority of patients at either end of the distribution,
evaluated as “not ill,”“severely ill,” or “extremely ill.”
By contrast, at the follow-up visit, the overall distribution
moved toward less severe forms of illness, with the majority
(75.0%) of patients classified as normal to mildly ill; over one
quarter of patients (26.0%) were classified as “not ill,” 21.0% as
“borderline ill,” and 28.0% as only “mildly ill.” Similar results were
seen when CGI was assessed by gender (data not shown).
www.frontiersin.org May 2013 | Volume 4 | Article 48 | 3
Agus et al. REVERT registry: clinical findings
Table 3 | Medical therapy.
Medical therapy % of patients on therapy
before entry
% of patients started on a
therapy at baseline (visit 1)
% of patients already on
therapy before visit 2
Additional % of patients who
started on a therapy at visit 2
Betahistine 26.6 66.6 66.1 21.5
Piracetam 11.5 11.0 14.0 3.3
Ginkgo biloba 5.7 5.2 6.4 3.1
Other vertigo therapy 4.7 5.9 5.1 1.9
Diuretics 5.3 3.1 4.6 0.9
Benzodiazepines 4.0 2.6 3.7 1.5
Antihistamines 1.7 1.3 1.7 0.9
Neuroleptics 1.9 1.1 1.5 0.6
Calcium antagonists 2.2 0.6 1.8 0.7
Homeopathics 1.1 0.8 0.5 0.5
Table 4 | Most frequent drug treatments by diagnosis.
Betahistine Piracetam Ginkgo biloba
Baseline Follow-up Baseline Follow-up Baseline Follow-up
Ménière’s disease n (%) (n=672) 595 (94.9) 453 (72.3) 106 (17.0) 69 (11.1) 72 (11.4) 48 (7.7)
BPPV n (%) (n=1,091) 933 (85.6) 724 (66.3) 174 (15.9) 119 (10.9) 125 (11.4) 70 (6.4)
Other vertigo n (%) (n=1,512) 1,377 (91.1) 1,112 (73.6) 435 (28.7) 263 (17.4) 170 (11.3) 139 (9.2)
Peripheral vestibular vertigo n (%) (n=832) 763 (91.7) 627 (75.4) 170 (20.4) 126 (15.1) 69 (8.3) 58 (7.0)
FIGURE 1 | Clinical global impression at baseline visit and follow-up (n= 4,192 at visit 1; n=3,566 at visit 2).
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Data on the change of severity of the illness from baseline
to follow-up showed that generally the greatest changes in sta-
tus were seen in the patients originally classified as more severely
or markedly ill and the greatest percentage of patients evaluated
as worsening were amongst those initially classified with milder
forms of illness. For example, 100.0% of patients assessed as
the “most extremely ill” improved their clinical status at follow-
up. However, only 40.1% of patients classified as “borderline ill,”
improved at follow-up. Figure 2 illustrates the results from those
patients assessed as having improved at follow-up based on the
severity of their illness (CGI-S) at baseline.
Assessment of change by diagnosis suggested that the most
impressive changes were seen in patients with BPPV; 66.7% of
those who were “extremely ill” at baseline were “not ill at all” at
6 months follow-up, and 40.8% who were “markedly ill” at base-
line were reported as “not at all ill” at follow-up. Patients with
“other vertigo of peripheral origin” also showed major improve-
ments from baseline to follow-up; however, those with MD had
the least impressive changes. Table 5 documents these changes by
showing the patients who were classified as having recovered com-
pletely (i.e., not at all ill) at follow-up from each diagnostic group
by CGI at baseline.
FIGURE 2 | Change in severity of illness; percentage of patients classified as “improved” at follow-up according to baseline CGI-S category.
Table 5 | Proportion of patients in each severity class having recovered during the registry according to CGI evaluation.
CGI evaluation Total
population (%)
Ménière’s
disease (%)
BPPV (%) Peripheral vestibular
vertigo (%)
Other
vertigo (%)
Change from visit 1 To visit 2
“Among the most extremely ill patients” “Normal (not at all ill)” 33.3 0.0 66.7 0.0 40.0
“Severely ill” 20.5 8.3 29.4 13.3 25.0
“Markedly ill” 25.9 19.9 40.8 12.3 27.7
“Moderately ill” 21.7 17.8 27.3 19.6 20.9
“Mildly ill” 27.1 35.2 35.4 25.2 20.9
“Borderline ill” 40.1 33.3 45.2 39.5 38.7
BPPV; benign paroxysmal positional vertigo.
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For CGI-C, according to the treating physician at follow-up, the
majority of patients (91.0%) had improved during the 6 months
from baseline to follow-up, with 39.5% “very much improved,”
35.4% “much improved,” and 16.4% “minimally improved.”
Figure 3 illustrates the results from CGI-C, where the change
of clinical impression showed no considerable differences in dis-
tribution according to gender with 92.4% of males “improving”
compared with 90.8% of females. When stratified by age, again, no
substantial differences were seen. For example, 92.0% of patients
in the 31–40 year group “improved” compared with 92.1% in the
71–80 year group.
SAFETY
Safety records showed one serious adverse event was reported dur-
ing the duration of the registry; this was assessed to be unrelated
to treatment.
DISCUSSION
The aim of the REVERT registry was to provide large-scale, multi-
national real-world data on vertigo and its management. This
included medical history (co-morbid conditions and treatment),
details about treatment prescribed at first and second visit and
clinical impressions about the course of the disease over a 6-
month period. The majority of patients were female, over 40 years
of age, and almost half had co-morbid cardio-vascular disease.
While epidemiologic data on the prevalence of specific dizziness
and vertigo disorders are scarce (Neuhauser, 2007), these find-
ings are in line with other published data. For example in a
national survey from Taiwan, mean age was 55 years with a ratio
of 1:1.96 of men to women (Lai et al., 2011) and in a US sur-
vey of emergency room visits for dizziness, mean age was 51 years
with 61.0% female (Newman-Toker et al., 2008). Medical history
results from our study show the high prevalence of medical condi-
tions, such as cardio-vascular disorders, hormonal dysfunctions,
and psychiatric disorders. These results are consistent with other
series which suggest that the most frequent diagnostic category in
patients admitted in emergency departments for acute dizziness
is oto-vestibular, but that general medical diagnoses (especially
cardio-vascular) are highly prevalent in this acute care popula-
tion (Newman-Toker et al., 2008). In the general practice set-
ting, the three most common diagnoses of vertigo (accounting
for 93.0% of all patient presentations) are BPPV, acute periph-
eral vestibulopathy (vestibular neuritis or labyrinthitis), and MD
(Halmagyi and Cremer, 2000). The results from this series are sim-
ilar; the most common diagnoses for vertigo being of peripheral
vestibular origin and BPPV. It needs to be noted that the case-
report form did not ask for migraine, which explains why neither
migraine with or without aura nor vestibular migraine appear in
our results.
Betahistine was the most frequently prescribed treatment in
this study; it was already prescribed to 26.0% of patients prior to
enrollment and was prescribed to nearly two thirds of patients at
first visit (66.0%). Our results suggest that MD was the diagnosis
in which betahistine was most commonly prescribed but they also
show that it was being used in 86.0% of patients with BPPV. Other
data on the treatment and management of vertigo in “real-life”
clinical practice are limited, but a recent observational study, simi-
lar to the current study, reported that betahistine was prescribed in
over half (∼56.0%) the patients at new diagnosis (Benecke et al.,
2010).
Other therapies recorded in the REVERT registry included
piracetam, ginkgo biloba, diuretics, benzodiazepines and antihis-
tamines. With the exception of piracetam, these were used in less
than 6.0% of patients at each observation. Piracetam is an estab-
lished treatment with several indications including vertigo. It was
prescribed in 14.0% of patients in this study and more often in
the group of patients with “other vertigo” than in any other group.
Ginkgo biloba extract is used clinically in the treatment of inner
FIGURE 3 | Proportion of patients with changes in illness according to CGI-C results at follow-up.
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ear disorders such as hearing loss, vertigo, and tinnitus; however,
recent evidence in support of its effectiveness is lacking.
At baseline, CGI-S scores suggested that almost half of patients
were classified as “moderately ill” (43.0%) while 4.0% were con-
sidered to be “severely ill” and 7.5% “borderline ill.” Over the
course of the REVERT registry, the severity of vertigo was reported
to decrease from baseline visit to follow-up at 6 months and the
proportions of patients in these groups altered accordingly. Only
19.0% were “moderately ill” at 6 months, and only 1.0% “severely
ill.” Results from the CGI-C showed that 91.0% of patients were
thought to have improved over the course of the registry, with
nearly 40.0% of patients classified as “very much improved.”
How much of this improvement was the result of treatment and
how much was due to spontaneous recovery of symptoms, is not
clear.
Spontaneous recovery is known to be common and reported
rates of spontaneous complete resolution of BPPV range from
20 to 80% at 1 month of repositioning treatment (Hornibrook,
2011). The American Academy of Otolaryngology, Head and
Neck Surgery Clinical Practice Guideline for BPPV recommends
that 1 month should be the standard interval after treatment
for retesting (Bhattacharyya et al., 2008). Patients who were
“markedly ill” appeared to be the most likely to improve over
the course of the registry, despite results suggesting that those
who were “moderately ill” received the highest application rate
of medical therapies. This further supports the idea that many
of the patients might have had spontaneous resolution of their
conditions.
This registry-based, observational study has several limita-
tions. The drawbacks associated with such studies are well-known;
invalid conclusions can result when, for example, there are insuf-
ficient quality and depth to the data, potential sources of bias,
and significant missing data. The data collected during this study
were limited to medical diagnosis, clinical global assessment, and
treatment. The diagnoses were not validated, and there is no infor-
mation on diagnosis definitions which could mean that these
differed from country to country and institution to institution.
The CGI is widely used and yet is also associated with several
known limitations; it lacks validation, there is no specific inter-
viewer guide available, and the response format used to assess
change or severity of illness is often ambiguous (Kadouri et al.,
2007). This study included over 4,000 patients at outset but nearly
18.0% were lost to follow-up. There may be several reasons for
non-attendance at follow-up and spontaneous recovery could be a
major cause. Change of treatment during the course of the registry
cannot be tracked with any certainty and the records suggest that
treatment may have been stopped and then re-started at follow-
up, but precise details are lacking. Lastly, this was a multi-national
study involving countries with different languages, cultures, and
national approaches to health care. As a result there is likely to
be a large amount of heterogeneity in the data, which again make
robust conclusions difficult to interpret.
Despite these drawbacks registries are useful tools which allow
for long-term, large-scale data collection in a real-world setting,
and are used regularly for pharmacovigilance, safety monitoring,
and to understand the epidemiology and burden of disease. Whilst
patient registries cannot offer comparable robustness to controlled
clinical trials, it is important to remember that real-world scenar-
ios are uncontrolled in their nature, and well-managed registries
can provide a wealth of information and valuable insight into the
actual clinical experience. The results from this registry can help
to inform primary care physicians; vestibular vertigo accounts for
a considerable healthcare burden, which suggests that diagnosis
and treatment of frequent vestibular conditions are important
issues in primary care (Neuhauser et al., 2008). Currently, little
is known about the drugs most commonly prescribed for vertigo,
compliance with these therapies and their overall effect on illness;
this study provides some evidence in this context. This study also
highlights a key point in the management of these patients – i.e.,
that most improve. Thus, an important clinical implication is that
physicians who diagnose and treat patients with vertigo can give a
likely favorable prognosis.
In conclusion, our results showed that betahistine was used
to treat the majority of patients in the registry and that 93.0%
of patients had improved after 6 months follow-up, with nearly
40.0% of patients classified as “very much improved.” This indi-
cates a considerable reduction in illness severity, some of which is
likely to be the result of pharmacological support. Further studies
are necessary to confirm these results and more consistent and
up-to-date guidelines are needed for the management of patients
with vertigo.
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